橡皮鱼
Lv5
820 积分
2022-10-22 加入
-
Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment
20天前
已完结
-
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
20天前
已完结
-
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)
21天前
已完结
-
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
1个月前
已完结
-
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1个月前
已完结
-
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
6个月前
已完结
-
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
6个月前
已完结
-
Aging of the human choriocapillaris: Evidence that early pericyte damage can trigger endothelial changes
7个月前
已完结
-
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
7个月前
已完结
-
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
7个月前
已完结